Asset profile

Mezigdomide

Small molecule

Phase 3underway

Evidence outlook · registrational

Multiple Myeloma: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-01-10.

How the evidence outlook works ↗

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (3)
October 2026 (2)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-10-01 · NCT06645678 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2026-10-12 · NCT05372354 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2026 (1)
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2026-11-30 · NCT03989414 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (4)
January 2027 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-01-10 · NCT05519085 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-05-01 · NCT06627751 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-05-31 · NCT06988488 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
January 2029 (1)
Phase 1/2Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia …Recruiting
Est. primary completion 2029-01-16 · NCT07356154 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2035 (1)
December 2035 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2035-12 · NCT06892522 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.